Table 1.
Discontinuation from PP3M.
| Clinical outcome after 2 years (PP3M) | ||
|---|---|---|
| n = 186 | ||
| Outcome 2 years after initiating PP3M [n (%)] | ||
| Continuation | 110 | (59.1) |
| Discontinuation | 62 | (33.3) |
| Attrition | 14 | (7.5) |
| n = 62 | ||
| Reasons for discontinuation [n (%)] | ||
| Patient refusal | 18 | (29.0) |
| Perceived inefficacy | 15 | (24.2) |
| Adverse effects | 11 | (17.7) |
| Patient request | 6 | (9.7) |
| Need more flexible dose adjustment | 4 | (6.5) |
| Independent health condition | 3 | (4.8) |
| Discharged from mental health services | 3 | (4.8) |
| Age concern (>65 years old) | 2 | (3.2) |
| Next medication (3 months after last depot) [n (%)] | ||
| PP1M | 29 | (46.8) |
| No medication | 21 | (33.9) |
| Risperidone (oral) | 5 | (8.1) |
| Aripiprazole (LAI) | 2 | (3.2) |
| Aripiprazole (oral) | 1 | (1.6) |
| Clozapine (oral) | 1 | (1.6) |
| Flupenthixol (LAI) | 1 | (1.6) |
| Haloperidol (LAI) | 1 | (1.6) |
| Haloperidol (oral) | 1 | (1.6) |
| n = 14 | ||
| Reasons for attrition [n (%)] | ||
| Lost to follow-up a | 8 | (57.1) |
| Died b | 6 | (42.9) |
Abbreviations: LAI, long-acting injection; PP3M, Paliperidone 3-monthly.
a
Lost to follow up: left country (n = 4), missing person (n = 2), changed trust (n = 1), and disengagement (n = 1).
b
Deaths classified using ePJS and not at a systems level: unknown (n = 2), heroin overdose (n = 1), natural causes (n = 1), nonadherence to diabetes medication (n = 1), and sepsis (n = 1).